| Outcome Measures: |
Primary: Renal Function, To evaluate renal function in Belatacept treated recipients of intermediate risk MAPI score allografts in terms of estimated glomerular filtration rate (eGFR, calculated using the MDRD formula) assessed at 12 months. The 12 month eGFR will be compared to existing cohorts of calcineurin inhibitor treated patients with MAPI scores above 8., 12 months | Secondary: Rejection rate, Secondary objectives include the biopsy proven rejection rates at 12 months and comparison to existing cohorts of calcineurin inhibitor treated patients., 12 months|Graft survival, Secondary objectives include renal allograft survival at 12 months., 12 months|MAPI biopsy score, Secondary objectives include the MAPI score at 3 and 12 months. The MAPI score change compared to baseline in the study group will be important in comparison to existing cohorts of calcineurin inhibitor treated patients, to determine whether calcineurin free-regimens are associated with both functional and histologic differences as compared to calcineurin based therapies., 12 months|Patient survival, Secondary objectives include patient survival at 12 months., 12 months
|
